OPS 202

Drug Profile

OPS 202

Alternative Names: 68Ga-OPS202; OPS202; SOMscan

Latest Information Update: 06 Sep 2016

Price : $50

At a glance

  • Originator OctreoPharm Sciences
  • Class Imaging agents; Peptides; Radiopharmaceutical diagnostics
  • Mechanism of Action Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Neuroendocrine tumours
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Neuroendocrine tumours

Most Recent Events

  • 06 Sep 2016 Phase-II clinical trials in Neuroendocrine tumours (Diagnosis) in Switzerland (Parenteral) before September 2016 (Ipsen pipeline, September 2016)
  • 01 Jun 2015 OctreoPharm Sciences completes a phase I/II trial in Neuroendocrine tumours (diagnosis) in Switzerland (Parenteral) (NCT02162446)
  • 16 Oct 2014 OPS 202 receives Orphan Drug status for Neuroendocrine tumours (Diagnosis) in USA
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top